There are no guidelines for the appropriate use of CBD oil. CBD oil is usually delivered sublingually (under the tongue). Most oils are sold in 30-milliliter (mL) bottles with a dropper cap.
CBD’s exact mechanism of action is unclear. Unlike THC, CBD has a relatively low affinity for cannabinoid receptors in the brain. These are the molecules to which THC binds to elicit its psychoactive effects.
For this study, nine healthy men took either 600 mg of CBD or the same dose of a placebo. According to the researcher, those treated with CBD had lower blood pressure before and after exposure to stressful stimuli (including exercise or extreme cold).
Dosage and Preparation
However, the effect of CBD on each addiction type was often very different. With opioid addiction, for example, CBD showed little effect in minimizing withdrawal symptoms in the absence of THC. By contrast, CBD on its own appeared effective in minimizing drug-seeking behaviors in users of cocaine, methamphetamine, and other psychostimulant drugs.
According to a 2012 study in the Journal of Experimental Medicine, rats injected with inflammatory chemicals in their hind feet experienced less inflammation and neuropathic pain when treated with an oral dose and spinal injection of CBD.
To avoid interactions, tell your doctor and pharmacist about all prescription, over-the-counter, herbal, or recreational drugs you are taking.
CBD oil is an extract of Cannabis indica or Cannabis sativa—the same plants that, when dried, make marijuana. CBD oil is believed by some to treat pain, reduce anxiety, and stimulate appetite in the same way that marijuana does, but without its psychoactive effects. CBD has also shown promise in treating certain types of seizures.
Schneider T, Zurbriggen L, Dieterle M, et al. Pain response to cannabidiol in induced acute nociceptive pain, allodynia, and hyperalgesia by using a model mimicking acute pain in healthy adults in a randomized trial (CANAB I). Pain. 2021. doi: 10.1097/j.pain.0000000000002310. View abstract.
Consroe P, Sandyk R, Snider SR. Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 1986;30(4):277-82. View abstract.
Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr 2008;30(3):271-80. View abstract.
Wade, D. T., Makela, P., Robson, P., House, H., and Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult.Scler. 2004;10(4):434-441. View abstract.
Matsuyama SS, Fu TK. In vivo cytogenetic effects of cannabinoids. J Clin Psychopharmacol 1981;1(3):135-40. View abstract.
Devinsky O, Marsh E, Friedman D, et la. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016 Mar;15(3):270-8. View abstract.
Monti JM. Hypnoticlike effects of cannabidiol in the rat. Psychopharmacology (Berl) 1977;55(3):263-5. View abstract.